Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug-drug conjugates of MEK and Akt inhibitors for RAS-mutant cancers.

Bioorganic & medicinal chemistry - 15 Mar 2024

Fujita Hikaru, Arai Sachiko, Arakawa Hiroshi, Hamamoto Kana, Kato Toshiyuki, Arai Tsubasa, Nitta Nanaka, Hotta Kazuki, Hosokawa Natsuko, Ohbayashi Takako, Takahashi Chiaki, Inokuma Yasuhide, Tamai Ikumi, Yano Seiji, Kunishima Munetaka, Watanabe Yoshihiro

Abstract excerpt

Controlling RAS mutant cancer progression remains a significant challenge in developing anticancer drugs. Whereas Ras G12C-covalent binders have received clinical approval, the emergence of further mutations, along with the activation of Ras-related proteins and signals, has led to resistance to Ras binders. To discover novel compounds to overcome this bottleneck, we focused on the concurrent and sustained...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Protein Kinase Inhibitors
Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Cell Line, Tumor

Share to Mitogen-Activated Protein Kinase Kinases

Share to Neoplasms

Share to Proto-Oncogene Proteins c-akt

Share to Signal Transduction

Source

Identifiers

PMID: 38457912
DOI: 10.1016/j.bmc.2024.117674

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug-drug conjugates of MEK and Akt inhibitors for RAS-mutant cancers.PMID 38457912Read ↗

Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRASG12D.Semantic proximity Read ↗

A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal CancerSemantic proximity Read ↗

Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor modelsSemantic proximity Read ↗

Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020-2023).Semantic proximity Read ↗

Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer.Semantic proximity Read ↗

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatmentSemantic proximity Read ↗

Antitumor Activity in <i>RAS</i> -Driven Tumors by Blocking AKT and MEKSemantic proximity Read ↗

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.Semantic proximity Read ↗

Small-molecule RAS/RAF Binding Inhibitors Allosterically Disrupt RAF Conformation and Exert Efficacy Against a Broad Spectrum of RAS-driven CancersSemantic proximity Read ↗

Discovery of novel spiro compound as RAF kinase inhibitor with in vitro potency against KRAS mutant cancer.Semantic proximity Read ↗

Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.Semantic proximity Read ↗

Tailoring Ras-pathway--inhibitor combinations for cancer therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.